Consolidation in the Spinal Implant Market
Executive Summary
This is the second big deal in the spinal implant market in the last three months. With its acquisition of Acromed, DePuy establishes itself as a strong Number 2 in what company officials believe is the fastest growing market in orthopedics today. Moreover, it did so at a fraction of the price Sulzer paid to get SpineTech just a couple of years earlier. While industry officials shake their heads at Sulzer's largesse, company officials are betting that SpineTech's cage technology represents a breakthrough product in spinal implants.
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.